's Bulletin Board Post A Reply
my profile login | register | search | faq | forum home

»'s Bulletin Board » Hot Stocks Free for All ! » ALMI,IESV,GMED loaded up for 2004 » Post A Reply

Post A Reply
Login Name:
Message Icon: Icon 1     Icon 2     Icon 3     Icon 4     Icon 5     Icon 6     Icon 7    
Icon 8     Icon 9     Icon 10     Icon 11     Icon 12     Icon 13     Icon 14    

HTML is not enabled.
UBB Code™ is enabled.


Instant Graemlins Instant UBB Code™
Smile   Frown   Embarrassed   Big Grin   Wink   Razz  
Cool   Roll Eyes   Mad   Eek!   Confused   BadOne  
Good Luck   More Crap   Wall Bang   Were Up   Were Down    
Insert URL Hyperlink - UBB Code™   Insert Email Address - UBB Code™
Bold - UBB Code™   Italics - UBB Code™
Quote - UBB Code™   Code Tag - UBB Code™
List Start - UBB Code™   List Item - UBB Code™
List End - UBB Code™   Image - UBB Code™

What is UBB Code™?

Disable Graemlins in this post.


T O P I C     R E V I E W
bingo2004  - posted
ALMI,IESV,GMED loaded up for 2004
TRSTURGUT-18  - posted

I have a heavy amount invested in GMED and have been accumulating.I think it will also be large in 2004...What peaks your interest
in GMED.


Icon  - posted
I may be mistaken, but; it seems as though Genomed is a very poor investment. Why are you buying when the company paints (below) a negative picture? Is their some major catalyst that you know about?

"If we are unable to obtain sufficient financing, then we will be unable to conduct our plan of operations, which may negatively impact development of our brand name and reputation. Our alternative plan of operations is to collect revenues only as a Next Generation Disease Management company. In the event that we do not obtain adequate financing we may have to liquidate our business and undertake any or all of the following actions: o Sell or dispose of our assets, if any; o Pay our liabilities in order of priority, if we have available cash to pay such liabilities; o If any cash remains after we satisfy amounts due to our creditors, distribute any remaining cash to our shareholders in an amount equal to the net market value of our net assets; o File a Certificate of Dissolution with the State of Florida to dissolve our corporation and close our business; o Make the appropriate filings with the Securities and Exchange Commission so that we will no longer be required to file periodic and other required reports with the Securities and Exchange Commission, if, in fact, we are a reporting company at that time; and o Make the appropriate filings with the National Association of Security Dealers to affect a delisting of our common stock, if, in fact, our common stock is trading on the OTC Bulletin Board at that time."


Purl Gurl  - posted
Bingo, you need to read my posts on the
registered board and over at Raging Bull.

Don't know if this information means much
of anything, but you should consider it,
related to Atlas Mining.

I sent email to Jacobson asking specifically
about those environmental issues.

Purl Gurl

Purl Gurl  - posted
Good research DOES turn up surprises!

This is snipped from further research:

"Atlas Consolidated Mining & Development Corp.
said...rehabilitation and reopening
of the Philippines' ... Minoro Mining &
Exploration Corp., majority owner of Atlas."

Appears the news report I developed, shared
in my previous article, did not identify the
correct Atlas Mining company. I am hoping
this is the case and it does appear so.

I will share with you what Jacobson has
to say about this and share with you his
response to my first email inquiry.

Purl Gurl

You will need to be a registered participant
here to read the complete thread on this
on a different All Stocks com board.

bingo2004  - posted
WHY GMED - new credibility -

GenoMed's Universal Approach to Viral Diseases, Including the Flu and SARS, to be Tested by NIAID

ST. LOUIS--(December 18, 2003)--GenoMed Inc. ("the Company" or "GenoMed") (National Quotation Bureau’s Pink Sheets Symbol GMED) announced today that it has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to test the Company's compounds in tissue culture assays to evaluate potential activity against influenza (the flu), West Nile virus, and SARS. Preclinical testing by the NIAID does not constitute an endorsement by the NIAID of GenoMed’s clinical trial.

Prevailing dogma holds that people who die from viral diseases--especially the very young and the very old--are immunocompromised and lack the ability to fight back against the virus. But autopsy results show a very strong immune response. Except in obviously immunocompromised people taking steroids or chemotherapy, it's the host's initial immune response, not overgrowth of the virus, that kills the host. For bacterial disease like anthrax, it's the opposite: unchecked growth of the bacterium liquefies organs.

Respiratory viruses like influenza, Hantavirus, RSV, and SARS cause death due to an acute respiratory distress-like syndrome (ARDS). ARDS is caused by an overly exuberant innate immune response. The host's initial immune response--whether moderate or excessive--not viral overgrowth, appears to determine whether the host lives or dies.

For novel viruses like this year's flu virus, the SARS coronavirus, and West Nile virus, the body has no memory of having ever seen the virus, so it can't coat the virus with pre-existing antibodies or calm the rage of immune effector cells with soothing suppressor T cells. The whole point of vaccination is to have pre-existing antibodies and lymphocytes with "memory" for the virus present when the virus eventually infects the host. Vaccination creates suppressor T cells with specific memory for the virus as well as coating antibodies. Without a competent suppressor limb, the immune response can become unbalanced, leading to organ damage in the host.

GenoMed believes it has discovered a way to accomplish the equivalent of vaccination against all viruses, a kind of "universal vaccine" against most viral diseases. The method involves blocking angiotensin II, an approach already known to be extremely safe from its use in hundreds of millions of patients since 1978.

Angiotensin II is important in getting the innate immune response started, because angiotensin I-converting enzyme (ACE), the enzyme which produces angiotensin II, is expressed on macrophages and T cells when these cells get activated. All immune cells, including macrophages, T and B cells, and neutrophils, contain type 1 receptors for angiotensin II. Blocking angiotensin II production with a suitable ACE inhibitor at a suitable dose, or the action of angiotensin II at type 1 receptors with an angiotensin II receptor blocker (ARB), is therefore expected to tone down the host's initial immune response. This is equivalent to what a good vaccine does. GenoMed's approach should decrease mortality from most viral infections, and may even hasten recovery from the common cold.

The patient's blood pressure should be the guide as to whether an ACE inhibitor or an ARB is chosen.

Said Dr. David Moskowitz, GenoMed's Chief Medical Officer and CEO, "While the NIAID is testing efficacy of our approach in model systems, anyone in the world can test it for themselves. This is especially important for people getting sicker rather than recovering as fast as expected from the flu or SARS. The Internet now makes it possible for anybody to enroll in our free clinical trials at any time of day or night anywhere in the world, simply by going to our website and clicking on the relevant trial. Once they enter their email address so that we can follow up with them, they'll be able to download the 2 documents they'll need to show their physician in order to get started immediately on our trial. A family member could easily do this for a child getting worse with the flu, for example."

The drugs GenoMed uses are safe enough to allow for their preventive use, and are available in every corner drug store. Most physicians are already comfortable using them to treat high blood pressure. Angiotensin II receptor blockers at extremely low doses appear to be effective against overactivity of the immune system without lowering blood pressure at all.

To volunteer for one of GenoMed's free clinical trials, go to

About GenoMed

GenoMed, Inc. is a Next Generation Disease Management(TM) whose mission is to improve patient outcomes by identifying the molecular pathways that cause disease. A St. Louis Business Journal article ( first reported that the company has applied for patents based on its finding that the ACE gene is associated with a large number of common diseases including virtually all autoimmune diseases.

For questions, please contact David W. Moskowitz MD, MA(Oxon.), FACP at 314-977-0110, FAX 314-977-0042, email:, or visit GenoMed at

This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.’s (the Company’s) treatments. The words or phrases "ought to,” “should,” "could," “may,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether GenoMed's approach will prove to be effective in cell culture or animal models of viral disease; (b) whether GenoMed's approach will prove to be effective in human cases of viral disease such as the flu and SARS; (c) whether GenoMed's server will hold up to international demand; (d) whether we will have sufficient financing to conduct our research and development; and (e) our research and development being subject to other economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


bingo2004  - posted
Also GMED is keeping its O.S. and burn rate low

and CEO is answering all shareholder questions - Link


bingo2004  - posted
My picks dated 1/2/2004 for 2004 profits

GMED .045 and under
ALMI .14 and under
IESV .05 and under
EDIG .56 and under
All of these have great potential to
move much higher.


Do the DD all these picks have great news coming out.

Sell for profits, and ride the free shares



man4apenny  - posted
Originally posted by bingo2004:
My picks dated 1/2/2004 for 2004 profits

GMED .045 and under
ALMI .14 and under
IESV .05 and under
EDIG .56 and under
All of these have great potential to
move much higher.


Do the DD all these picks have great news coming out.

Sell for profits, and ride the free shares


Well look likes IESV's potential has arrived Hit .075 today on hi volume. This could well be the pick of '04

Contact Us | Message Board Home

© 1997 - 2018 All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2